' Акцијски курс '

Datum	Telix Pharmaceuticals Cena akcije
30. 9. 2024.	20,69 undefined
27. 9. 2024.	20,41 undefined
26. 9. 2024.	20,65 undefined
25. 9. 2024.	20,19 undefined
24. 9. 2024.	20,93 undefined
23. 9. 2024.	20,65 undefined
20. 9. 2024.	20,08 undefined
19. 9. 2024.	18,67 undefined
18. 9. 2024.	17,82 undefined
17. 9. 2024.	18,47 undefined
16. 9. 2024.	17,89 undefined
13. 9. 2024.	19,13 undefined
12. 9. 2024.	19,02 undefined
11. 9. 2024.	18,29 undefined
10. 9. 2024.	18,12 undefined
9. 9. 2024.	17,57 undefined
6. 9. 2024.	17,74 undefined
5. 9. 2024.	17,44 undefined
4. 9. 2024.	17,34 undefined
3. 9. 2024.	17,67 undefined
2. 9. 2024.	18,07 undefined

Datum	Telix Pharmaceuticals Promet	Telix Pharmaceuticals EBIT	Telix Pharmaceuticals Profit
2028e	1,60 milijardi undefined	474,44 mil. undefined	0 undefined
2027e	1,28 milijardi undefined	315,14 mil. undefined	0 undefined
2026e	1,28 milijardi undefined	348,36 mil. undefined	269,44 mil. undefined
2025e	970,70 mil. undefined	224,25 mil. undefined	163,18 mil. undefined
2024e	774,53 mil. undefined	118,62 mil. undefined	96,37 mil. undefined
2023	502,55 mil. undefined	17,61 mil. undefined	5,21 mil. undefined
2022	160,10 mil. undefined	-90,81 mil. undefined	-104,08 mil. undefined
2021	7,60 mil. undefined	-76,95 mil. undefined	-80,51 mil. undefined
2020	5,21 mil. undefined	-35,60 mil. undefined	-44,89 mil. undefined
2019	3,49 mil. undefined	-28,36 mil. undefined	-27,87 mil. undefined
2018	195.140,00 undefined	-17,51 mil. undefined	-13,83 mil. undefined
2017	0 undefined	-6,16 mil. undefined	-6,38 mil. undefined

	Promet	EBIT	Profit
2017	0 AUD	-6,16 mil. AUD	-6,38 mil. AUD
2018	195.140,00 AUD	-17,51 mil. AUD	-13,83 mil. AUD
2019	3,49 mil. AUD	-28,36 mil. AUD	-27,87 mil. AUD
2020	5,21 mil. AUD	-35,60 mil. AUD	-44,89 mil. AUD
2021	7,60 mil. AUD	-76,95 mil. AUD	-80,51 mil. AUD
2022	160,10 mil. AUD	-90,81 mil. AUD	-104,08 mil. AUD
2023	502,55 mil. AUD	17,61 mil. AUD	5,21 mil. AUD
2024e	774,53 mil. AUD	118,62 mil. AUD	96,37 mil. AUD
2025e	970,70 mil. AUD	224,25 mil. AUD	163,18 mil. AUD
2026e	1,28 milijardi AUD	348,36 mil. AUD	269,44 mil. AUD
2027e	1,28 milijardi AUD	315,14 mil. AUD	0 AUD
2028e	1,60 milijardi AUD	474,44 mil. AUD	0 AUD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e
0	0	0,00	0,01	0,01	0,16	0,50	0,77	0,97	1,28	1,28	1,60
-	-	-	66,67	40,00	2.185,71	213,75	54,18	25,32	32,27	0,08	24,92
-	-	-	60,00	71,43	58,75	62,55	-	-	-	-	-
0	0	0	3,00	5,00	94,00	314,00	0	0	0	0	0
-6,00	-17,00	-28,00	-35,00	-76,00	-90,00	17,00	118,00	224,00	348,00	315,00	474,00
-	-	-933,33	-700,00	-1.085,71	-56,25	3,39	15,25	23,09	27,12	24,53	29,55
-6,00	-13,00	-27,00	-44,00	-80,00	-104,00	5,00	96,00	163,00	269,00	0	0
-	116,67	107,69	62,96	81,82	30,00	-104,81	1.820,00	69,79	65,03	-	-
127,99	202,12	233,44	257,27	282,21	310,64	323,71	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

48,76	25,77	44,60	77,95	22,04	116,33	123,24
0	0	0,75	0,16	0,73	39,35	64,78
0	0	12,26	14,03	20,12	6,57	7,66
0	0,64	0,54	0,63	3,45	8,48	17,31
0,45	1,01	0,53	0,86	1,21	2,51	31,95
49,21	27,42	58,68	93,63	47,54	173,23	244,93
0,01	0,23	1,90	4,82	6,33	18,84	30,49
0	0	0	0	0	0	12,26
0	1,17	0,08	0,18	0,21	0,33	0,59
1,51	36,31	37,72	54,97	51,63	53,47	104,82
0	3,14	4,22	4,22	4,10	5,52	4,85
0,04	0	0	0	0	3,97	20,45
1,55	40,85	43,93	64,19	62,27	82,12	173,45
50,75	68,27	102,61	157,82	109,81	255,35	418,38

55,56	72,05	115,94	167,06	170,84	370,97	446,27
0	0	0	0	0	0	0
-6,27	-19,20	-45,80	-88,34	-167,53	-290,40	-291,05
-0,02	53,86	-62,00	299,00	-1.153,00	-562,00	-5.414,00
0	0	0	0	0	0	-0,90
49,29	52,90	70,08	79,02	2,16	80,01	148,91
0,28	3,25	6,96	5,81	11,88	16,81	32,84
0,25	0,48	0,45	0,48	11,49	31,80	55,01
0,59	3,38	2,72	12,90	13,98	36,31	75,66
345,43	0	0	0	0	0	0
0	1,13	0,49	0,77	0,63	0,64	1,56
1,47	8,24	10,63	19,96	37,98	85,56	165,06
0	0,60	1,64	1,44	1,91	9,81	15,89
0,33	4,37	3,17	0	0	0	0
0	10,59	17,09	57,41	67,77	79,99	76,10
0,33	15,56	21,90	58,85	69,67	89,79	91,98
1,80	23,80	32,53	78,80	107,66	175,35	257,05
51,09	76,71	102,61	157,82	109,81	255,35	405,96

2017	2018	2019	2020	2021	2022	2023
0	0	0	0	0	-104,00	0
0	0	0	0	0	5,00	0
0	0	0	0	0	0	0
0	1,00	9,00	11,00	12,00	18,00	-14,00
0	0	0	0	0	35,00	0
0	0	0	0	0	0	0
0	0	0	0	0	-2,00	-10,00
-6,00	-20,00	-23,00	1,00	-59,00	-63,00	23,00
0	0	0	0	-1,00	-13,00	-10,00
0	-2,00	0	-1,00	-2,00	-16,00	-25,00
0	-2,00	0	0	-1,00	-3,00	-14,00
0	0	0	0	0	0	0
0	0	-1,00	0	0	1,00	3,00
58,00	0	45,00	35,00	3,00	181,00	6,00
54,00	0	42,00	34,00	2,00	174,00	10,00
-2,00	-	-1,00	-	-	-7,00	-
0	0	0	0	0	0	0
42,00	-45,00	-13,00	24,00	-127,00	13,00	56,00
-6,04	-20,75	-23,80	1,64	-60,67	-77,83	13,09
0	0	0	0	0	0	0

Telix Pharmaceuticals Bruto marža	Telix Pharmaceuticals Profitna marža	Telix Pharmaceuticals EBIT marža	Telix Pharmaceuticals Profitna marža
2028e	62,56 %	29,58 %	0 %
2027e	62,56 %	24,54 %	0 %
2026e	62,56 %	27,15 %	21,00 %
2025e	62,56 %	23,10 %	16,81 %
2024e	62,56 %	15,32 %	12,44 %
2023	62,56 %	3,50 %	1,04 %
2022	59,29 %	-56,72 %	-65,01 %
2021	66,46 %	-1.012,97 %	-1.059,90 %
2020	61,17 %	-682,89 %	-861,06 %
2019	27,03 %	-813,74 %	-799,63 %
2018	62,56 %	-8.970,50 %	-7.087,13 %
2017	62,56 %	0 %	0 %

	Bruto marža	EBIT marža	Profitna marža
2017	62,56 %	0 %	0 %
2018	62,56 %	-8.970,50 %	-7.087,13 %
2019	27,03 %	-813,74 %	-799,63 %
2020	61,17 %	-682,89 %	-861,06 %
2021	66,46 %	-1.012,97 %	-1.059,90 %
2022	59,29 %	-56,72 %	-65,01 %
2023	62,56 %	3,50 %	1,04 %
2024e	62,56 %	15,32 %	12,44 %
2025e	62,56 %	23,10 %	16,81 %
2026e	62,56 %	27,15 %	21,00 %
2027e	62,56 %	24,54 %	0 %
2028e	62,56 %	29,58 %	0 %

Datum	Telix Pharmaceuticals Prihod po akciji	Telix Pharmaceuticals EBIT po akciji	Telix Pharmaceuticals Dobit po akciji
2028e	4,79 undefined	0 undefined	0 undefined
2027e	3,84 undefined	0 undefined	0 undefined
2026e	3,83 undefined	0 undefined	0,81 undefined
2025e	2,90 undefined	0 undefined	0,49 undefined
2024e	2,31 undefined	0 undefined	0,29 undefined
2023	1,55 undefined	0,05 undefined	0,02 undefined
2022	0,52 undefined	-0,29 undefined	-0,34 undefined
2021	0,03 undefined	-0,27 undefined	-0,29 undefined
2020	0,02 undefined	-0,14 undefined	-0,17 undefined
2019	0,01 undefined	-0,12 undefined	-0,12 undefined
2018	0,00 undefined	-0,09 undefined	-0,07 undefined
2017	0 undefined	-0,05 undefined	-0,05 undefined

	Prihod po akciji	EBIT po akciji	Dobit po akciji
2017	0 AUD	-0,05 AUD	-0,05 AUD
2018	0,00 AUD	-0,09 AUD	-0,07 AUD
2019	0,01 AUD	-0,12 AUD	-0,12 AUD
2020	0,02 AUD	-0,14 AUD	-0,17 AUD
2021	0,03 AUD	-0,27 AUD	-0,29 AUD
2022	0,52 AUD	-0,29 AUD	-0,34 AUD
2023	1,55 AUD	0,05 AUD	0,02 AUD
2024e	2,31 AUD	0 AUD	0,29 AUD
2025e	2,90 AUD	0 AUD	0,49 AUD
2026e	3,83 AUD	0 AUD	0,81 AUD
2027e	3,84 AUD	0 AUD	0 AUD
2028e	4,79 AUD	0 AUD	0 AUD

	Broj akcija
2017	127,99 mil. Aktien
2018	202,12 mil. Aktien
2019	233,44 mil. Aktien
2020	257,27 mil. Aktien
2021	282,21 mil. Aktien
2022	310,64 mil. Aktien
2023	323,71 mil. Aktien
2024e	323,71 mil. Aktien
2025e	323,71 mil. Aktien
2026e	323,71 mil. Aktien
2027e	323,71 mil. Aktien
2028e	323,71 mil. Aktien

Datum	Procena EPSa	EPS-Actual	Kvartal izveštaja
30. 6. 2024.	0,13	0,09 (-30,10 %)	2024 Q2
31. 12. 2023.	0,08	0,06 (-25,43 %)	2023 Q4
30. 6. 2023.	0,03	-0,05 (-233,14 %)	2023 Q2
31. 12. 2022.	-0,05	-0,10 (-105,94 %)	2022 Q4
30. 6. 2022.	-0,11	-0,23 (-120,00 %)	2022 Q2
31. 12. 2021.	-0,08	-0,17 (-117,22 %)	2021 Q4
30. 6. 2021.	-0,10	-0,12 (-17,77 %)	2021 Q2
31. 12. 2020.	0	-0,10 (0 %)	2020 Q4

%	Ime	Акције	Promena	Datum
6,94051 %	Behrenbruch (Christian P. Ph.D.)	23.228.298	153.298	24. 1. 2024.
6,77519 %	Kluge (Andreas)	22.675.000	0	24. 1. 2024.
3,27097 %	Grand Decade Developments Ltd.	10.947.181	0	24. 1. 2024.
2,29366 %	The Vanguard Group, Inc.	7.676.347	2.911.488	31. 3. 2024.
2,22737 %	UV-Cap GmbH & Co KG	7.454.500	-70.500	24. 1. 2024.
1,77166 %	Oncidium Foundation	5.929.331	-310.029	24. 1. 2024.
1,56016 %	Norges Bank Investment Management (NBIM)	5.221.507	1.919.856	31. 12. 2023.
1,42029 %	Vanguard Investments Australia Ltd.	4.753.394	9.373	29. 2. 2024.
1,08425 %	Nelson (Mark)	3.628.750	0	31. 12. 2023.
0,98545 %	Lightpoint Medical Ltd	3.298.073	3.298.073	24. 1. 2024.
0,93309 %	BlackRock Institutional Trust Company, N.A.	3.122.822	1.151	31. 3. 2024.
0,68135 %	Sage Capital Pty Ltd.	2.280.325	2.280.325	30. 11. 2023.
0,59215 %	Yelwac Pty. Ltd.	1.981.804	-400.000	24. 1. 2024.
0,58067 %	Netwealth Investments Ltd.	1.943.357	-12.082	24. 1. 2024.
0,51791 %	Aglub Holdings Pty. Ltd.	1.733.342	1.733.342	24. 1. 2024.
0,45412 %	BetaShares Capital Ltd.	1.519.823	28.474	31. 3. 2024.
0,41612 %	MLC Asset Management	1.392.649	-37.464	31. 12. 2023.
0,34361 %	McCann (Harry Kevin)	1.150.000	0	31. 12. 2023.
0,32256 %	Pendal Group Limited	1.079.529	0	31. 12. 2023.
0,31113 %	Portland Investment Counsel Inc.	1.041.264	0	31. 12. 2023.
0,27865 %	Pengana Capital Group Limited	932.572	0	31. 12. 2023.
0,26984 %	Nuveen LLC	903.093	-741.074	31. 3. 2024.
0,24377 %	BlackRock Investment Management (Australia) Ltd.	815.827	16.859	31. 3. 2024.
0,19059 %	State Street Global Advisors Australia Ltd.	637.870	-1.704	31. 3. 2024.
0,17778 %	Skinner (Jann)	595.000	0	31. 12. 2023.
0,17060 %	Handelsbanken Kapitalförvaltning AB	570.953	505.000	31. 3. 2024.
0,16799 %	Polar Capital LLP	562.234	286.494	31. 12. 2023.
0,16348 %	State Street Global Advisors (US)	547.132	22.029	29. 2. 2024.
0,16340 %	FIL Investment Management (Australia) Limited	546.849	0	29. 2. 2024.
0,15540 %	Charles Schwab Investment Management, Inc.	520.074	196.215	31. 3. 2024.
0,07800 %	California State Teachers Retirement System	261.034	17.027	30. 6. 2023.
0,07705 %	MLC Investments Limited	257.865	-8.067	31. 12. 2023.
0,07309 %	Hayward (C)	244.621	244.621	31. 12. 2023.
0,06215 %	BlackRock Advisors (UK) Limited	207.992	3.195	31. 3. 2024.
0,05647 %	Evelyn Partners Investment Management LLP	189.000	0	29. 2. 2024.
0,05426 %	Origin Asset Management LLP	181.602	0	29. 2. 2024.
0,05005 %	Fidelity International	167.507	508	31. 1. 2024.
0,04878 %	Geode Capital Management, L.L.C.	163.260	0	29. 2. 2024.
0,04754 %	EntrepreneurShares LLC	159.122	0	31. 1. 2024.
0,04482 %	Bellevue Asset Management AG	150.000	0	29. 2. 2024.
0,03735 %	Valeix (R)	125.000	0	31. 12. 2023.
0,03660 %	Credit Suisse Funds AG	122.499	-8.014	29. 2. 2024.
0,02991 %	UBS Asset Management (UK) Ltd.	100.103	0	29. 2. 2024.
0,02846 %	Olson (Tiffany)	95.235	0	31. 12. 2023.
0,02747 %	Harbour Asset Management Limited	91.924	10.030	31. 12. 2023.
0,02604 %	Dimensional Fund Advisors, L.P.	87.162	87.162	31. 3. 2024.
0,01861 %	Mercer Global Investments Management Ltd	62.276	-4.206	31. 3. 2024.
0,01858 %	Florida State Board of Administration	62.193	62.193	30. 9. 2022.
0,01782 %	Zürcher Kantonalbank (Asset Management)	59.623	0	31. 1. 2024.
0,01768 %	Northern Trust Global Investments Limited	59.178	0	31. 12. 2023.
0,01747 %	BlackRock Asset Management Canada Limited	58.478	0	31. 3. 2024.
0,01537 %	State Street Global Advisors Ireland Limited	51.426	715	31. 3. 2024.
0,01343 %	BlackRock Investment Management (UK) Ltd.	44.939	0	31. 12. 2023.
0,01255 %	Maybank Asset Management Singapore Pte. Ltd.	41.989	0	29. 2. 2024.
0,01214 %	KLP Fondsforvaltning AS	40.623	0	29. 2. 2024.
0,00901 %	AllianceBernstein L.P.	30.138	0	29. 2. 2024.
0,00739 %	DWS Investment GmbH	24.743	107	31. 3. 2024.
0,00643 %	Vident Investment Advisory, LLC	21.506	0	31. 5. 2023.
0,00577 %	Mackenzie Financial Corporation	19.325	5.442	31. 3. 2024.
0,00572 %	Victory Capital Management Inc.	19.148	-71.956	30. 9. 2023.
0,00512 %	Legal & General Investment Management Ltd.	17.129	0	29. 2. 2024.
0,00395 %	Pictet Asset Management Ltd.	13.214	0	30. 11. 2023.
0,00365 %	UBS Asset Management (Switzerland)	12.231	0	31. 1. 2024.
0,00356 %	Vanguard Global Advisers LLC	11.914	4.538	31. 3. 2024.
0,00300 %	Harris Associates L.P.	10.024	0	29. 2. 2024.
0,00240 %	Connor, Clark & Lunn Investment Management Ltd.	8.048	0	30. 11. 2023.
0,00194 %	Smith (D)	6.500	0	31. 12. 2023.
0,00120 %	Northern Trust Investments, Inc.	4.018	0	31. 3. 2024.
0,00117 %	Global X Management (AUS) Limited	3.931	456	31. 3. 2024.
0,00108 %	Milliman Financial Risk Management, LLC	3.606	0	31. 3. 2024.
0,00095 %	Invesco Capital Management LLC	3.176	272	31. 3. 2024.
0,00085 %	Tredje AP Fonden	2.854	-99.433	31. 12. 2023.
0,00026 %	First Trust Advisors L.P.	863	0	29. 2. 2024.
0,00024 %	Rakuten Investment Management, Inc.	800	800	31. 10. 2023.
0,00003 %	FIL Investment Management (Hong Kong) Limited	102	-11	29. 2. 2024.
0 %	Firetrail Investments Pty Limited	0	-232.544	31. 3. 2023.
0 %	ETF Architect	0	-215.495	30. 9. 2023.
0 %	RAM Active Investments S.A.	0	-15.398	31. 12. 2023.
0 %	TOBAM	0	-9.343	29. 2. 2024.
0 %	EAM Investors, LLC	0	-150.657	30. 9. 2023.
0 %	Quaero Capital LLP	0	-235.876	30. 9. 2022.
0 %	Fideuram Asset Management (Ireland) dac	0	-18.000	29. 2. 2024.
0 %	SEI Investments Management Corporation	0	-35.589	31. 10. 2023.
0 %	Artisan Partners Limited Partnership	0	-1.466.937	31. 3. 2023.
0 %	Platinum Asset Management	0	-62.909	31. 8. 2023.
0 %	Baillie Gifford & Co.	0	-193.941	31. 10. 2023.
0 %	Amundi Asset Management, SAS	0	-19.194	30. 11. 2022.
0 %	Lazard Asset Management, L.L.C.	0	-70.150	31. 8. 2023.

Ime	Odnos	Dvonedeljna korelacija	Korelacija za jedan mesec	Trojmešečna korelacija	Šestomesečna korelacija	Jednogodišnja korelacija	Dvogodišnja korelacija
Eckert & Ziegler Strahlen	DobavljačKlijent	0,81	0,62	0,79	0,79	0,34	0,77
Merck	DobavljačKlijent	0,75	0,42	-0,03	0,64	0,66	0,91
Mauna Kea Technologies O	DobavljačKlijent	0,68	0,33	0,09	0,60	-	-0,44
Grand Pharmaceutical Group	DobavljačKlijent	0,66	0,52	0,51	0,70	0,10	-0,10
Heidelb Ph	DobavljačKlijent	0,66	0,26	-0,68	-0,29	-0,27	0,34
Yantai Dongcheng Biochems A	DobavljačKlijent	0,38	0,49	0,65	0,80	0,06	-0,61
Amgen	DobavljačKlijent	0,34	0,57	-0,58	-0,55	-0,51	-0,51
HSBC Holdings	DobavljačKlijent	0,23	0,47	0,56	-0,36	-0,15	0,61
Cardinal Health	DobavljačKlijent	0,05	0,48	-0,59	-0,72	-0,62	-0,01
JPMorgan Chase	DobavljačKlijent	-0,18	0,43	0,81	0,82	0,49	0,86

What values and corporate philosophy does Telix Pharmaceuticals represent?

Telix Pharmaceuticals Ltd represents a strong commitment to improving the diagnosis and treatment of cancer. With a focus on molecularly targeted radiation therapy, the company aims to develop innovative radiopharmaceuticals that can deliver more precise and effective cancer treatments. Telix Pharmaceuticals embraces a patient-centered approach, continually striving to enhance patient outcomes and improve quality of life. The company is dedicated to fostering collaborations, driving scientific advancements, and delivering transformative therapies to individuals battling cancer. Telix Pharmaceuticals Ltd stands as a beacon of innovation, aiming to revolutionize the field of cancer medicine with its cutting-edge technologies and unwavering dedication to making a difference.

In which countries and regions is Telix Pharmaceuticals primarily present?

Telix Pharmaceuticals Ltd primarily operates in several countries and regions, including Australia, the United States, Europe, and Japan.

What significant milestones has the company Telix Pharmaceuticals achieved?

Telix Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully completed its Phase III clinical trial for TLX591-CDx, a prostate cancer imaging agent. Additionally, Telix Pharmaceuticals received regulatory approval in the United States, Europe, and Canada for TLX591-CDx, allowing for its commercialization. Another notable achievement is the successful completion of a collaboration agreement with China Grand Pharma, expanding Telix's presence in the Chinese market. Furthermore, Telix Pharmaceuticals entered into a licensing agreement with ANMI SA, enhancing its product portfolio for molecular imaging. These achievements highlight Telix Pharmaceuticals' commitment to developing innovative solutions in the field of radiopharmaceuticals.

What is the history and background of the company Telix Pharmaceuticals?

Telix Pharmaceuticals Ltd is an innovative biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for cancer diagnosis and treatment. Established in 2016, Telix has rapidly grown into a global player in the molecularly targeted radiation therapy field. The company has successfully acquired and developed a diverse portfolio of diagnostic and therapeutic products, leveraging its cutting-edge technology and strategic partnerships. Telix has made significant progress in clinical trials, regulatory approvals, and commercialization efforts, demonstrating its commitment to improving patient outcomes in oncology. With its dedicated team and robust pipeline, Telix Pharmaceuticals Ltd is poised to revolutionize cancer management through personalized and targeted radiopharmaceuticals.

Who are the main competitors of Telix Pharmaceuticals in the market?

The main competitors of Telix Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the same sector, focusing on molecularly targeted radiation (MTR) therapies and diagnostic imaging products for oncology. These competitors include established players such as Advanced Accelerator Applications SA (a Novartis company), Bayer AG, Curium Pharmaceuticals, and Progenics Pharmaceuticals. Telix Pharmaceuticals Ltd distinguishes itself through its innovative radiopharmaceutical solutions, strategic collaborations, and ongoing clinical trials.

In which industries is Telix Pharmaceuticals primarily active?

Telix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Telix Pharmaceuticals?

The business model of Telix Pharmaceuticals Ltd revolves around the development and commercialization of molecularly targeted radiation (MTR) products. As a leading biopharmaceutical company, Telix focuses on producing innovative diagnostic and therapeutic solutions for patients suffering from cancer. By utilizing its expertise in radiopharmaceuticals and molecular targeting, Telix aims to enhance the precision and efficacy of cancer diagnosis, imaging, and treatment. Through collaborations with various partners, Telix strives to bring advanced diagnostic imaging technologies and personalized treatment options to healthcare professionals and patients worldwide. Telix Pharmaceuticals Ltd plays a crucial role in improving patient outcomes and advancing the field of nuclear medicine.

Koji P/E odnos ima Telix Pharmaceuticals 2024?

P/E odnos Telix Pharmaceuticals iznosi 69,50.

Koji je KUV za Telix Pharmaceuticals 2024?

KUV kompanije Telix Pharmaceuticals iznosi 8,65.

Koji AlleAktien kvalitetni skor ima Telix Pharmaceuticals?

AlleAktien kvalitativni skor za Telix Pharmaceuticals je 3/10.

Koliki je prihod od Telix Pharmaceuticals 2024?

očekivana Telix Pharmaceuticals promet je 774,53 mil. AUD.

Koliki je profit kompanije Telix Pharmaceuticals 2024?

Dobit očekivana Telix Pharmaceuticals je 96,37 mil. AUD.

Шта ради Telix Pharmaceuticals?

Telix Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development and commercialization of diagnostic technologies and therapeutic products for oncology.

Kolika je Telix Pharmaceuticals dividenda?

Telix Pharmaceuticals isplaćuje dividendu od 0 AUD raspoređenu preko isplata u toku godine.

Koliko često Telix Pharmaceuticals isplaćuje dividendu?

Dividenda za Telix Pharmaceuticals trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

Šta je Telix Pharmaceuticals ISIN?

ISIN od Telix Pharmaceuticals je AU000000TLX2.

Šta je Telix Pharmaceuticals WKN?

WKN od Telix Pharmaceuticals je A2H7JK.

Koji je Telix Pharmaceuticals berzanski simbol?

Oznaka za praćenje akcija kompanije Telix Pharmaceuticals je TLX.AX.

Kolika je dividenda koju isplaćuje Telix Pharmaceuticals?

U poslednjih 12 meseci, Telix Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Telix Pharmaceuticals će verovatno isplatiti dividendu od 0 AUD.

Kolika je dividendna prinosa za Telix Pharmaceuticals?

Dividendski prinos od Telix Pharmaceuticals trenutno iznosi .

Kada Telix Pharmaceuticals isplaćuje dividendu?

Telix Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Telix Pharmaceuticals?

Telix Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Telix Pharmaceuticals?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 AUD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Telix Pharmaceuticals?

Telix Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Telix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Telix Pharmaceuticals od 1. 10. 2024. u iznosu od 0 AUD, morali ste da imate akciju u depou pre Ex-dana 1. 10. 2024..

Kada je Telix Pharmaceuticals poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 1. 10. 2024..

Kolika je bila dividenda od Telix Pharmaceuticals u godini 2023?

U godini 2023 kompanija Telix Pharmaceuticals je isplatila 0 AUD kao dividende.

U kojoj valuti Telix Pharmaceuticals isplaćuje dividendu?

Dividende od Telix Pharmaceuticals se isplaćuju u AUD.

Direktne emisije	—
Indirektne emisije iz kupljene energije	—
Indirektne emisije unutar lanca vrednosti	—
CO₂ emisije	—
Strategija redukcije CO₂	✅
Ugalj energija	❌
Atomska energija	❌
Eksperimenti na životinjama	✅
Pelz & Leder	—
Pesticidi	—
Palmino ulje	—
Tabak	❌
Gentechnika	❌
Koncept klime	—
Održivo šumarstvo	—
Pravila o reciklaži	❌
Ekološka ambalaža	✅
Opasne materije	❌
Potrošnja i efikasnost goriva	❌
Potrošnja i efikasnost vode	❌

Udeo žena zaposlenih	49
Udeo žena u menadžmentu	—
Udeo azijskih zaposlenih	—
Udeo azijskog menadžmenta	—
Udeo hispansko/latinskih zaposlenih	—
Udeo hispano/latino menadžmenta	—
Udeo crnačkih zaposlenih	—
Udeo crnačkog menadžmenta	—
Udeo belih zaposlenih	—
Udeo belačkog menadžmenta	—
Sadržaji za odrasle	❌
Alkohol	❌
Odbrana	—
oružje	❌
Kockanje	❌
Ugovori o vojsci	❌
Koncept ljudskih prava	✅
Koncept zaštite podataka	—
Zaštita na radu i zdravlje	✅
Katolički	✅

Izveštaj o održivosti	❌
Angažovanje zainteresovanih strana	✅
Politika povlačenja	❌
Antimonopolsko pravo	❌

Berza	Telix Pharmaceuticals Тикер
ASX	TLX.AX
PNK	TLPPF

Telix Pharmaceuticals Тикер	Telix Pharmaceuticals FIGI
TLX:AU	BBG00HZHXWM5
TLX:AT	BBG00HZHXWN4
TLX:AH	BBG00HZHXWS9
T3X:TH	BBG00J9YR656
TLX2EUR:X2	BBG00JB5XWC4
TLX2EUR:XB	BBG00JB5XWD3
TLX2EUR:XH	BBG00JB5XWG0
TLX2EUR:XF	BBG00JB5XWJ7
TLX2EUR:XE	BBG00JB5XWL4
TLX2EUR:XJ	BBG00JB5XWM3
TLX2EUR:XL	BBG00JB5XWN2
TLX2EUR:XG	BBG00JB5XWP0
TLX2EUR:XO	BBG00JB5XWQ9
TLX2EUR:XS	BBG00JB5XWV3
TLX2EUR:XA	BBG00JB5XWX1
TLX2EUR:E1	BBG00JB5XWY0
TLX2EUR:XT	BBG00JB5XWZ9
TLX2EUR:XW	BBG00JB5XX05
TLX2EUR:XU	BBG00JB5XX14
TLX2EUR:XV	BBG00JB5XX23
TLX2EUR:XM	BBG00JB5XX32
TLX2EUR:EU	BBG00JB5XX69
TLX2EUR:XX	BBG00JN8P604
TLPPF:US	BBG00LJTBT58
TLPPF:PQ	BBG00LJTBTL0
TLPPF:UV	BBG00LJTBTM9
TLX2AUD:XH	BBG00QFSBKZ9
TLX2AUD:XF	BBG00QFSBL14
TLX2AUD:XE	BBG00QFSBL32
TLX2AUD:XL	BBG00QFSBL50
TLX2AUD:XG	BBG00QFSBL69
TLX2AUD:XO	BBG00QFSBL78
TLX2AUD:XA	BBG00QFSBLC2
TLX2AUD:XT	BBG00QFSBLF9
TLX2AUD:XW	BBG00QFSBLG8
TLX2AUD:XU	BBG00QFSBLH7
TLX2AUD:XV	BBG00QFSBLK3
TLX2AUD:XM	BBG00QFSBLL2
TLX2AUD:EU	BBG00QFSBLS5
T3X:GR	BBG00YG2LCL0
T3X:GM	BBG00YG2LCR4
T3X:GB	BBG00YG2LCS3
TLX2USD:X2	BBG010C6R0N6
TLX2USD:XH	BBG010C6R0Z3
TLX2USD:XF	BBG010C6R181
TLX2USD:XE	BBG010C6R1J9
TLX2USD:XL	BBG010C6R1V5
TLX2USD:XG	BBG010C6R1Z1
TLX2USD:XO	BBG010C6R243
TLX2USD:XA	BBG010C6R2Q9
TLX2USD:E1	BBG010C6R2V3
TLX2USD:XT	BBG010C6R305
TLX2USD:XW	BBG010C6R341
TLX2USD:XU	BBG010C6R396
TLX2USD:XV	BBG010C6R3L2
TLX2USD:XM	BBG010C6R3Q7
TLX2USD:XQ	BBG010C6R3W0
TLX2USD:XX	BBG010C6R412
TLX2USD:XZ	BBG010C6R467
TLX2USD:X1	BBG010C6R4J3
TLX2USD:EU	BBG010C6R9V8

Napravi najbolje investicije svog života. fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Cena

Cena

ТикерTLX.AX

ISINAU000000TLX2

WKNA2H7JK

Telix Pharmaceuticals Cena akcije

Kurs

Pregled

Intraday funkcija

Ukupan prinos i relativna promena cene

Interpretacija i investiranje

Telix Pharmaceuticals Istorija kursa

Telix Pharmaceuticals Akcija Promet, EBIT, Dobit AU000000TLX2 · A2H7JK

Promet, Profit & EBIT

Razumevanje prometa, EBIT-a i prihoda

Godišnja analiza i poređenja

Koristite očekivanja za investiranje

Uvid u investicije

Telix Pharmaceuticals Prihod, dobit i EBIT istorija

Telix Pharmaceuticals Akcija Kennzahlen

GuV

Prihod i rast

Bruto marža

EBIT i EBIT marža

Prihod i rast

Izdate akcije

Interpretacija godišnje usporedbe

Očekivanja i prognoze

Bilans

Razumevanje bilansa

Sredstva

Obaveze

Kapital

Analiza iz godine u godinu

Interpretacija podataka

Telix Pharmaceuticals Акција Маргине AU000000TLX2 · A2H7JK

Margine

Razumevanje bruto marže

Analiza marže EBIT

Uvidi u maržu obrta

Tumačenje očekivanja

Analiza poređenja

Telix Pharmaceuticals Istorija margine

Telix Pharmaceuticals акција промет, EBIT, добит по акцији AU000000TLX2 · A2H7JK

Promet, EBIT i Zarada po deonici

Promet po deonici

EBIT po deonici

Prihod po deonici

Očekivane vrednosti

Telix Pharmaceuticals Promet, dobit i EBIT po akciji - istorija

Telix Pharmaceuticals Akcija i analiza akcija

Telix Pharmaceuticals Оцена према Fair Value

Fair Value

Razumevanje Fair Value

Fair Value zasnovan na dobitku

Fair Value zasnovan na prihodu

Fair Value zasnovan na dividendi

Očekivanja i prognoze

Uporedna analiza

Telix Pharmaceuticals Ocena na osnovu istorijskog KGV, EBIT i KUV

Telix Pharmaceuticals Broj akcija AU000000TLX2 · A2H7JK

Promet, EBIT i Zarada po deonici

Promet po deonici

EBIT po deonici

Prihod po deonici

Očekivane vrednosti

Telix Pharmaceuticals Procene zarade

Telix Pharmaceuticals Iznenađenja u zaradi

Eulerpool ESG ocena za akciju Telix Pharmaceuticals

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

👫 Social

🏛️ Governance

Životna sredina (Environment)

Društveno (Social)

Upravljanje preduzećem (Governance)

Telix Pharmaceuticals Akcija Struktura vlasništva

Telix Pharmaceuticals Upravni i Nadzorni odbor

Napravi najbolje investicije svog života.
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Тикер
TLX.AX

ISIN
AU000000TLX2

WKN
A2H7JK